Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Laxman 7-marker panel for prostate cancer

Laxman 7-marker panel for prostate cancer

Basics

Attributes

QA State: Curated
Short Name:

This 7-marker multiplex panel of urine transcripts outperforms PCA3 transcript alone for the detection of prostate cancer. The panel consists of PCA3, AMACR, ERG, GP73 (GOLPH2), SPINK1, TFF3, and TMPRSS2:ERG fusion.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Curated

This 7-marker panel has been shown to outperform serum PSA or PCA3 assays alone when used on sedimented urine from patients considered for prostate biopsy or prostatectomy.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html